Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of RYBREVANT ® (amivantamab-vmjw) Plus Chemotherapy for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Progressed on or after Osimertinib